Prospective observational study to evaluate the efficacy and safety of osimertinib by PK/PD/PGx analysis
Not Applicable
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000029995
- Lead Sponsor
- ational Cancer CEnter
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of osimertinib are studied in JPRN-UMIN000029995 for EGFR-mutated lung cancer?
How does osimertinib's efficacy compare to standard EGFR inhibitors in NSCLC patients with T790M mutations?
Which pharmacogenomic biomarkers predict osimertinib response in JPRN-UMIN000029995 lung cancer study?
What adverse events are associated with osimertinib in JPRN-UMIN000029995 and how are they managed?
Are there combination therapies with osimertinib being explored for EGFR-mutated lung cancer post-trial JPRN-UMIN000029995?